TWI912331B - 抗tau抗體 - Google Patents

抗tau抗體

Info

Publication number
TWI912331B
TWI912331B TW110125334A TW110125334A TWI912331B TW I912331 B TWI912331 B TW I912331B TW 110125334 A TW110125334 A TW 110125334A TW 110125334 A TW110125334 A TW 110125334A TW I912331 B TWI912331 B TW I912331B
Authority
TW
Taiwan
Prior art keywords
seq
specific binding
sequence shown
amino acid
binding molecule
Prior art date
Application number
TW110125334A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214686A (zh
Inventor
索曼 蘇木亞 巴利易爾
安德魯 賈斯汀 雷德克里夫 波爾特
查理斯 羅伯特 哈靈頓
克勞蒂 米歇爾 威斯奇克
穆罕默德 爾拉史杜
路易斯 克爾克 潘妮
理查 洛夫特豪斯
Original Assignee
英商Ｇｔ創新公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商Ｇｔ創新公司 filed Critical 英商Ｇｔ創新公司
Publication of TW202214686A publication Critical patent/TW202214686A/zh
Application granted granted Critical
Publication of TWI912331B publication Critical patent/TWI912331B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW110125334A 2020-07-10 2021-07-09 抗tau抗體 TWI912331B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
GBGB2010652.2 2020-07-10

Publications (2)

Publication Number Publication Date
TW202214686A TW202214686A (zh) 2022-04-16
TWI912331B true TWI912331B (zh) 2026-01-21

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110125334A TWI912331B (zh) 2020-07-10 2021-07-09 抗tau抗體

Country Status (10)

Country Link
US (1) US12624096B2 (enExample)
EP (1) EP4178980A1 (enExample)
JP (1) JP7796719B2 (enExample)
KR (1) KR20230038721A (enExample)
CN (1) CN116194479B (enExample)
AU (1) AU2021306653A1 (enExample)
CA (1) CA3185175A1 (enExample)
GB (1) GB202010652D0 (enExample)
TW (1) TWI912331B (enExample)
WO (1) WO2022008719A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample
WO2023135201A1 (en) * 2022-01-12 2023-07-20 Gtinvent Limited Method for detecting a tau protein fragment in a sample

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015004163A1 (en) * 2013-07-08 2015-01-15 Adx Neurosciences Anti-tau monoclonal antibodies
CN105324394A (zh) * 2012-12-21 2016-02-10 比奥根Ma公司 人抗-tau抗体
CN105899230A (zh) * 2013-11-27 2016-08-24 伊皮埃里安股份有限公司 治疗tau病变的方法
TW201821438A (zh) * 2016-12-07 2018-06-16 美商建南德克公司 抗-ｔａｕ抗體及使用方法
TW201836640A (zh) * 2017-03-28 2018-10-16 美商建南德克公司 治療神經退化性疾病之方法
CN109562167A (zh) * 2016-08-09 2019-04-02 伊莱利利公司 联合治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
DK2853293T3 (en) 2006-03-29 2018-01-22 Wista Lab Ltd Thioninium compounds and their use
CN104119294B (zh) 2006-03-29 2018-10-30 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物的制备方法
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2799746C (en) * 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
KR101231777B1 (ko) 2010-11-25 2013-02-08 부산대학교 산학협력단 ＧＳＫ３β 저해를 통한 타우 과인산화 저해제 탐색 방법
KR101888713B1 (ko) 2011-02-11 2018-08-14 위스타 레보레이토리스 리미티드 페노티아진 디아미늄 염 및 이의 용도
US20200030445A1 (en) 2015-06-12 2020-01-30 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN120305401A (zh) * 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
EP4463480A1 (en) * 2022-01-12 2024-11-20 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105324394A (zh) * 2012-12-21 2016-02-10 比奥根Ma公司 人抗-tau抗体
WO2015004163A1 (en) * 2013-07-08 2015-01-15 Adx Neurosciences Anti-tau monoclonal antibodies
CN105899230A (zh) * 2013-11-27 2016-08-24 伊皮埃里安股份有限公司 治疗tau病变的方法
CN109562167A (zh) * 2016-08-09 2019-04-02 伊莱利利公司 联合治疗
TW201821438A (zh) * 2016-12-07 2018-06-16 美商建南德克公司 抗-ｔａｕ抗體及使用方法
TW201836640A (zh) * 2017-03-28 2018-10-16 美商建南德克公司 治療神經退化性疾病之方法

Also Published As

Publication number Publication date
US20230257452A1 (en) 2023-08-17
EP4178980A1 (en) 2023-05-17
CN116194479B (zh) 2026-05-22
CN116194479A (zh) 2023-05-30
KR20230038721A (ko) 2023-03-21
WO2022008719A1 (en) 2022-01-13
US12624096B2 (en) 2026-05-12
JP7796719B2 (ja) 2026-01-09
TW202214686A (zh) 2022-04-16
CA3185175A1 (en) 2022-01-13
GB202010652D0 (en) 2020-08-26
JP2023533768A (ja) 2023-08-04
AU2021306653A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
US9849165B2 (en) Oligomer-specific amyloid beta epitope and antibodies
AU2020294348A1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
US12624096B2 (en) Anti-tau antibodies and methods of use thereof
US20230365665A1 (en) ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US11472869B2 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2015358641A1 (en) Antibody highly specifically recognizing turn structure at 22- and 23-positions in Amyloid Beta
RU2855123C1 (ru) Антитела против тау
US20250355001A1 (en) Method for detecting a tau protein fragment in a sample
US20170096476A1 (en) Methods and compositions related to amyloid-beta-42 oligomers
WO2014056934A1 (en) Modulator of quinolinic acid for use in the treatment of a neuropathological disease
HK1231887A1 (en) Oligomer-specific amyloid beta epitope and antibodies
AU2016208334A1 (en) Oligomer-specific amyloid beta epitope and antibodies
HK1185350B (en) Oligomer-specific amyloid beta epitope and antibodies